Icrucumab

From Wikipedia, the free encyclopedia
Icrucumab ?
Monoclonal antibody
Type Whole antibody
Source Human
Target VEGFR-1
Clinical data
Legal status ?
Identifiers
CAS number 1024603-92-6 N
ATC code None
UNII T7H0B1R64U YesY
Chemical data
Formula C6514H10024N1756O2032S42 
Mol. mass 146.8 kDa
 N (what is this?)  (verify)

Icrucumab is a human monoclonal antibody designed for the treatment of solid tumors.[1]

Icrucumab was developed by ImClone Systems Inc.

References

  1. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Icrucumab". American Medical Association. 
Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems
Bone ("-os-", "-s(o)-")
Human ("-osu-")
Humanized ("-sozu-")
Musculoskeletal ("-mul-")
Human ("-mulu-")
Circulatory ("-c(i[r])-")
Human ("-ciru-")
Mouse ("-ciro-")
Chimeric ("-cixi-")
Humanized ("-cizu-")
Neurologic ("-ne(u)(r)-")
Human ("-neru-")
Humanized ("-nezu-"/"-neuzu-")
Angiogenesis inhibitor ("-anibi-")
Humanized ("-anibizu-")


This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.